<p>生物制药公司（BioMarin Pharmaceutical Inc.）（NASDAQ:BMRN - 获取免费报告）周二交易中股价上涨 3.9%，在此之前 Truist Financial 将其目标价从 80.00 美元上调至 100.00 美元。Truist Financial 目前对该股票给予买入评级。生物制药的股价最高达到 61.40 美元，最后交易价为 61.5780 美元。在交易中，共成交 557,089 股，较平均交易量 2,192,203 股下降了 75%。该股票此前收盘价为 59.28 美元。</p>
<ul>
<li>生物制药股票能否满足华尔街的高期望？</li>
</ul>
<p>其他一些股票研究分析师最近也对 BMRN 发表了看法。Raymond James Financial 在 9 月 3 日的研究报告中开始覆盖生物制药公司，给予 “跑赢大盘” 评级，并设定 85.00 美元的目标价。摩根士丹利在 10 月 28 日的研究报告中将生物制药公司的目标价从 104.00 美元下调至 98.00 美元，并给予 “增持” 评级。Stifel Nicolaus 在 11 月 6 日的研究报告中重申 “持有” 评级，并将生物制药公司的目标价设定为 61.00 美元（较之前的 73.00 美元下调）。Sanford C. Bernstein 在 11 月 3 日的研究报告中将生物制药公司的目标价从 95.00 美元下调至 88.00 美元，并给予 “跑赢大盘” 评级。最后，Leerink Partners 在 12 月 3 日的研究报告中将生物制药公司的评级从 “跑赢大盘” 下调至 “市场表现”，并将其目标价从 82.00 美元下调至 60.00 美元。十六位投资分析师对该股票给予买入评级，八位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，生物制药公司目前的平均评级为 “适度买入”，平均目标价为 89.70 美元。</p>
<p><strong>获取我们关于生物制药公司的最新报告</strong></p>
<h2>生物制药公司新闻摘要</h2>
<ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
<p>以下是本周影响生物制药公司的主要新闻：</p>
<ul>
<li>积极情绪：Truist 将 BMRN 的目标价上调至 100 美元，并维持 “买入” 观点，指出与当前水平相比有较大上行空间——这是一个明确的看涨信号，可能在中期内支持该股票。Truist 目标价上调</li>
<li>积极情绪：生物制药同意以约 48 亿美元收购 Amicus Therapeutics，增加两种增长中的罕见病药物和一个晚期管线资产——这是一项变革性的交易，扩大了收入和在罕见病领域的研发深度。生物制药以 48 亿美元收购 Amicus</li>
<li>积极情绪：分析师在 Amicus 交易后对生物制药的看法变得更加乐观，认为此次合并具有增值潜力，并支持未来的增长预期。积极的分析师评论可以提升情绪和长期预期。分析师在收购 Amicus 后变得更加乐观</li>
<li>积极情绪：行业分析和看涨评论（例如，Seeking Alpha）强调生物制药在罕见病领域的领导地位和加速的产品销售（例如：Brineura 的增长），强化了收购 Amicus 的战略理由。Seeking Alpha：Amicus 收购激发热情</li>
<li>中性情绪：HC Wainwright 略微调整其目标价（至 60 美元），并保持中性评级——这是一个混合信号，相对于更激进的 Truist 目标提供了有限的上行信心。HC Wainwright 目标价变动</li>
<li>中性情绪：覆盖报告指出分析师在医疗保健领域的观点相互矛盾，反映出对交易经济学和像 Amicus 收购这样的交易整合风险的不同看法。分析师的混合评论往往会增加短期波动性。分析师观点相互矛盾</li>
<li>消极情绪：生物制药停止了 BMN 349（AATD 治疗）的开发，这是一个管线挫折，减少了该项目未来的上行潜力，并可能因失去一个潜在的长期资产而对短期情绪产生负面影响。生物制药结束 BMN 349 的开发</li>
</ul>
<h2>机构投资者对生物制药公司的看法</h2>
<p>机构投资者和对冲基金最近买卖了该股票的股份。Jump Financial LLC 在第二季度将其在生物制药公司的持股增加了 530.3%。Jump Financial LLC 目前拥有 291,217 股生物制药公司的股票，价值 16,008,000 美元，此前在上个季度又购买了 245,017 股。高盛集团在第一季度将其在生物制药公司的持股增加了 212.7%。高盛集团目前拥有 1,592,963 股生物制药公司的股票，价值 112,607,000 美元，此前在上个季度又购买了 1,083,512 股。AQR Capital Management LLC 在第二季度将其在生物制药公司的持股增加了 90.7%。AQR Capital Management LLC 目前拥有 5,580,573 股生物制药公司的股票，价值 306,429,000 美元，此前在上个季度又购买了 2,654,768 股。Covea Finance 在第二季度将其在生物制药公司的持股增加了 27.3%。Covea Finance 目前拥有 135,300 股生物制药公司的股票，价值 7,437,000 美元，此前在上个季度又购买了 29,000 股。最后，1832 Asset Management L.P.在第二季度购买了生物制药公司的新股份，价值约 1,431,000 美元。98.71% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>生物制药公司股价上涨 3.7%</h2>
<ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
<p>该公司的 50 日简单移动平均线为 53.81 美元，200 日简单移动平均线为 55.64 美元。该公司的市值为 118.1 亿美元，市盈率为 23.15，市盈增长比率为 1.02，贝塔值为 0.30。该公司的速动比率为 3.10，流动比率为 4.83，债务股本比率为 0.10。</p>
<p>拜玛林制药（NASDAQ:BMRN - 获取免费报告）于 10 月 27 日星期一发布了其季度财报。该生物技术公司报告本季度每股收益为 0.12 美元，低于市场共识预期的 0.32 美元，差距为 0.20 美元。该公司本季度的收入为 7.7613 亿美元，而市场共识预期为 7.8242 亿美元。拜玛林制药的净利润率为 16.82%，股本回报率为 9.53%。与去年同期相比，该公司的季度收入增长了 4.1%。在去年同期，该公司每股收益为 0.91 美元。拜玛林制药已将其 2025 财年的每股收益指导设定在 3.500-3.600 美元。股票分析师预计拜玛林制药将在当前年度发布每股收益 3.15 美元。</p>
<h2>关于拜玛林制药</h2>
<p>（获取免费报告）</p>
<p>拜玛林制药公司是一家生物制药公司，专注于开发和商业化针对罕见遗传和代谢疾病的治疗方案。该公司致力于通过利用酶替代疗法、小分子药物伴侣和基因治疗技术来满足未被满足的医疗需求。拜玛林总部位于加利福尼亚州诺瓦托，在美国和欧洲设有研发设施。</p>
<p>该公司的商业产品组合包括几种针对遗传疾病的已批准疗法。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过拜玛林制药</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>埃隆警告 “美国破产”。特朗普的计划在这里。</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在拜玛林制药吗？</h2>
<p>在考虑拜玛林制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而拜玛林制药并不在名单上。</p>
<p>虽然拜玛林制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

拜玛林制药

<p>在 Truist Financial 将 BioMarin Pharmaceutical 的目标股价从 80 美元上调至 100 美元并维持买入评级后，该公司的股票上涨了 3.9%。该股票交易价格为 61.5780 美元，交易量显著减少。分析师的评级各不相同，平均目标价为 89.70 美元。BioMarin 以 48 亿美元收购 Amicus Therapeutics 被视为积极举措，而停止 BMN 349 的开发则是一个挫折</p>

<p>BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) shares traded up 3.9% during trading on Tuesday after Truist Financial raised their price target on the stock from $80.00 to $100.00. Truist Financial currently has a buy rating on the stock. BioMarin Pharmaceutical traded as high as $61.40 and last traded at $61.5780. 557,089 shares changed hands during trading, a decline of 75% from the average session volume of 2,192,203 shares. The stock had previously closed at $59.28.</p>
<div class="lb-trans"><p>生物制药公司（BioMarin Pharmaceutical Inc.）（NASDAQ:BMRN - 获取免费报告）周二交易中股价上涨 3.9%，在此之前 Truist Financial 将其目标价从 80.00 美元上调至 100.00 美元。Truist Financial 目前对该股票给予买入评级。生物制药的股价最高达到 61.40 美元，最后交易价为 61.5780 美元。在交易中，共成交 557,089 股，较平均交易量 2,192,203 股下降了 75%。该股票此前收盘价为 59.28 美元。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>生物制药股票能否满足华尔街的高期望？</li>
</ul>
</div><p>A number of other equities research analysts have also recently weighed in on BMRN. Raymond James Financial initiated coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an &#34;outperform&#34; rating and a $85.00 price target for the company. Morgan Stanley dropped their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, October 28th. Stifel Nicolaus restated a &#34;hold&#34; rating and set a $61.00 price objective (down from $73.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, November 6th. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $95.00 to $88.00 and set an &#34;outperform&#34; rating for the company in a research report on Monday, November 3rd. Finally, Leerink Partners lowered BioMarin Pharmaceutical from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and decreased their price objective for the company from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Sixteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $89.70.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对 BMRN 发表了看法。Raymond James Financial 在 9 月 3 日的研究报告中开始覆盖生物制药公司，给予 “跑赢大盘” 评级，并设定 85.00 美元的目标价。摩根士丹利在 10 月 28 日的研究报告中将生物制药公司的目标价从 104.00 美元下调至 98.00 美元，并给予 “增持” 评级。Stifel Nicolaus 在 11 月 6 日的研究报告中重申 “持有” 评级，并将生物制药公司的目标价设定为 61.00 美元（较之前的 73.00 美元下调）。Sanford C. Bernstein 在 11 月 3 日的研究报告中将生物制药公司的目标价从 95.00 美元下调至 88.00 美元，并给予 “跑赢大盘” 评级。最后，Leerink Partners 在 12 月 3 日的研究报告中将生物制药公司的评级从 “跑赢大盘” 下调至 “市场表现”，并将其目标价从 82.00 美元下调至 60.00 美元。十六位投资分析师对该股票给予买入评级，八位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，生物制药公司目前的平均评级为 “适度买入”，平均目标价为 89.70 美元。</p>
</div><p><strong>Get Our Latest Report on BioMarin Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>获取我们关于生物制药公司的最新报告</strong></p>
</div><h2>BioMarin Pharmaceutical News Summary</h2>
<div class="lb-trans"><h2>生物制药公司新闻摘要</h2>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
</div><p>Here are the key news stories impacting BioMarin Pharmaceutical this week:</p>
<div class="lb-trans"><p>以下是本周影响生物制药公司的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Truist raised its price target on BMRN to $100 and initiated/maintained a &#34;buy&#34; view, citing large upside vs. current levels — a clear bullish signal that could support the stock over the medium term. Truist price target raise</li>
<li>Positive Sentiment: BioMarin agreed to acquire Amicus Therapeutics for ~$4.8B, adding two growing rare-disease drugs and a late-stage pipeline asset — a transformational deal that expands revenues and R&amp;D depth in rare-disease franchises. BioMarin to Buy Amicus for $4.8B</li>
<li>Positive Sentiment: Analysts have grown more bullish on BioMarin after the Amicus deal, viewing the combination as value-accretive and supportive of future growth expectations. Positive analyst commentary can lift sentiment and long-term estimates. Analysts grow more bullish after Amicus acquisition</li>
<li>Positive Sentiment: Industry write-ups and bullish commentaries (e.g., Seeking Alpha) highlight BioMarin’s rare-disease leadership and accelerating product sales (examples: Brineura growth), reinforcing the strategic rationale for the Amicus takeover. Seeking Alpha: Amicus buyout sparks enthusiasm</li>
<li>Neutral Sentiment: HC Wainwright adjusted its price target modestly (to $60) and kept a neutral rating — a mixed signal that provides limited upside conviction relative to the more aggressive Truist target. HC Wainwright PT change</li>
<li>Neutral Sentiment: Coverage pieces note conflicting analyst views across healthcare names, reflecting varying opinions on deal economics and integration risk for transactions like the Amicus acquisition. Mixed analyst commentary tends to increase short-term volatility. Analysts have conflicting sentiments</li>
<li>Negative Sentiment: BioMarin discontinued development of BMN 349 (AATD therapy), a pipeline setback that reduces future upside from that program and may weigh on near-term sentiment given the loss of a potential long-term asset. BioMarin ends development of BMN 349</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Truist 将 BMRN 的目标价上调至 100 美元，并维持 “买入” 观点，指出与当前水平相比有较大上行空间——这是一个明确的看涨信号，可能在中期内支持该股票。Truist 目标价上调</li>
<li>积极情绪：生物制药同意以约 48 亿美元收购 Amicus Therapeutics，增加两种增长中的罕见病药物和一个晚期管线资产——这是一项变革性的交易，扩大了收入和在罕见病领域的研发深度。生物制药以 48 亿美元收购 Amicus</li>
<li>积极情绪：分析师在 Amicus 交易后对生物制药的看法变得更加乐观，认为此次合并具有增值潜力，并支持未来的增长预期。积极的分析师评论可以提升情绪和长期预期。分析师在收购 Amicus 后变得更加乐观</li>
<li>积极情绪：行业分析和看涨评论（例如，Seeking Alpha）强调生物制药在罕见病领域的领导地位和加速的产品销售（例如：Brineura 的增长），强化了收购 Amicus 的战略理由。Seeking Alpha：Amicus 收购激发热情</li>
<li>中性情绪：HC Wainwright 略微调整其目标价（至 60 美元），并保持中性评级——这是一个混合信号，相对于更激进的 Truist 目标提供了有限的上行信心。HC Wainwright 目标价变动</li>
<li>中性情绪：覆盖报告指出分析师在医疗保健领域的观点相互矛盾，反映出对交易经济学和像 Amicus 收购这样的交易整合风险的不同看法。分析师的混合评论往往会增加短期波动性。分析师观点相互矛盾</li>
<li>消极情绪：生物制药停止了 BMN 349（AATD 治疗）的开发，这是一个管线挫折，减少了该项目未来的上行潜力，并可能因失去一个潜在的长期资产而对短期情绪产生负面影响。生物制药结束 BMN 349 的开发</li>
</ul>
</div><h2>Institutional Investors Weigh In On BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>机构投资者对生物制药公司的看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Jump Financial LLC raised its position in BioMarin Pharmaceutical by 530.3% during the second quarter. Jump Financial LLC now owns 291,217 shares of the biotechnology company's stock valued at $16,008,000 after purchasing an additional 245,017 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company's stock worth $112,607,000 after purchasing an additional 1,083,512 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company's stock worth $306,429,000 after purchasing an additional 2,654,768 shares in the last quarter. Covea Finance increased its position in shares of BioMarin Pharmaceutical by 27.3% during the 2nd quarter. Covea Finance now owns 135,300 shares of the biotechnology company's stock valued at $7,437,000 after purchasing an additional 29,000 shares during the last quarter. Finally, 1832 Asset Management L.P. purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $1,431,000. 98.71% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该股票的股份。Jump Financial LLC 在第二季度将其在生物制药公司的持股增加了 530.3%。Jump Financial LLC 目前拥有 291,217 股生物制药公司的股票，价值 16,008,000 美元，此前在上个季度又购买了 245,017 股。高盛集团在第一季度将其在生物制药公司的持股增加了 212.7%。高盛集团目前拥有 1,592,963 股生物制药公司的股票，价值 112,607,000 美元，此前在上个季度又购买了 1,083,512 股。AQR Capital Management LLC 在第二季度将其在生物制药公司的持股增加了 90.7%。AQR Capital Management LLC 目前拥有 5,580,573 股生物制药公司的股票，价值 306,429,000 美元，此前在上个季度又购买了 2,654,768 股。Covea Finance 在第二季度将其在生物制药公司的持股增加了 27.3%。Covea Finance 目前拥有 135,300 股生物制药公司的股票，价值 7,437,000 美元，此前在上个季度又购买了 29,000 股。最后，1832 Asset Management L.P.在第二季度购买了生物制药公司的新股份，价值约 1,431,000 美元。98.71% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>BioMarin Pharmaceutical Trading Up 3.7%</h2>
<div class="lb-trans"><h2>生物制药公司股价上涨 3.7%</h2>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
</div><p>The firm's 50-day simple moving average is $53.81 and its 200-day simple moving average is $55.64. The firm has a market capitalization of $11.81 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 1.02 and a beta of 0.30. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 53.81 美元，200 日简单移动平均线为 55.64 美元。该公司的市值为 118.1 亿美元，市盈率为 23.15，市盈增长比率为 1.02，贝塔值为 0.30。该公司的速动比率为 3.10，流动比率为 4.83，债务股本比率为 0.10。</p>
</div><p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). The firm had revenue of $776.13 million for the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The company's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.91 earnings per share. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>拜玛林制药（NASDAQ:BMRN - 获取免费报告）于 10 月 27 日星期一发布了其季度财报。该生物技术公司报告本季度每股收益为 0.12 美元，低于市场共识预期的 0.32 美元，差距为 0.20 美元。该公司本季度的收入为 7.7613 亿美元，而市场共识预期为 7.8242 亿美元。拜玛林制药的净利润率为 16.82%，股本回报率为 9.53%。与去年同期相比，该公司的季度收入增长了 4.1%。在去年同期，该公司每股收益为 0.91 美元。拜玛林制药已将其 2025 财年的每股收益指导设定在 3.500-3.600 美元。股票分析师预计拜玛林制药将在当前年度发布每股收益 3.15 美元。</p>
</div><h2>About BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>关于拜玛林制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.</p>
<div class="lb-trans"><p>拜玛林制药公司是一家生物制药公司，专注于开发和商业化针对罕见遗传和代谢疾病的治疗方案。该公司致力于通过利用酶替代疗法、小分子药物伴侣和基因治疗技术来满足未被满足的医疗需求。拜玛林总部位于加利福尼亚州诺瓦托，在美国和欧洲设有研发设施。</p>
</div><p>The company's commercial portfolio includes several approved therapies targeting inherited disorders.</p>
<div class="lb-trans"><p>该公司的商业产品组合包括几种针对遗传疾病的已批准疗法。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过拜玛林制药</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>埃隆警告 “美国破产”。特朗普的计划在这里。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在拜玛林制药吗？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑拜玛林制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而拜玛林制药并不在名单上。</p>
</div><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然拜玛林制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

拜玛林制药（NASDAQ:BMRN）因分析师上调评级，股价上涨 3.9%